Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy

NCT02449655 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

27

Enrollment

OTHER

Sponsor class

Stopped lack of efficacy

Conditions

Advanced Gastric Adenocarcinoma

Interventions

DRUG: AZD5363
DRUG: paclitaxel
DRUG: AZD2014
DRUG: paclitaxel

Sponsor

Samsung Medical Center